RxDoctor Payments Data

Hannah Brooks

Psychiatric/Mental Health · Cumming, GANPI 1104467356

Payments from drug & device makers

$1,284in general payments, 2019–2025

Across 71 payments — averaging $18.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$248
  • Johnson & Johnson$227
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$223
  • Takeda Pharmaceuticals U.S.A., Inc.$134
  • Axsome Therapeutics, Inc.$112
  • Supernus Pharmaceuticals, Inc.$94
  • plus $246 from 8 others

What the payments were for

  • Food & beverage$1,284100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,284 in reported general payments places this provider in the 75th percentile of 900 psychiatric/mental health providers in Georgia.

See all psychiatric/mental health providers in Georgia

Medicare billing

Part B allowed, 2024
$11,248
Medicare patients
23
Services billed
119

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole18$42,472
Invega SustennaPaliperidone Palmitate12$39,539
VraylarCariprazine Hcl15$21,109
Desvenlafaxine Succinate ErDesvenlafaxine Succinate12$3,087
Ziprasidone Hcl35$1,569
Doxepin Hcl21$980
Bupropion XlBupropion Hcl62$969
Venlafaxine Hcl ErVenlafaxine Hcl70$946
Olanzapine38$942
Aripiprazole45$813
Buspirone Hcl18$617
Quetiapine Fumarate65$602
Lamotrigine57$576
Duloxetine Hcl24$568
Prazosin Hcl39$535

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$71$42,47218 claims
Johnson & JohnsonInvega Sustenna$227$39,53912 claims
AbbVieVraylar$248$21,10915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 900 psychiatric/mental health providers in Georgia.

Other psychiatric/mental health in Cumming

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →